Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report

Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricit...

Full description

Bibliographic Details
Main Authors:	Yuya Fujita, Masao Nawata, Atsushi Nagayasu, Kazuki Someya, Kazuyoshi Saito, Yoshiya Tanaka
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	Case Reports in Rheumatology
Online Access:	http://dx.doi.org/10.1155/2019/5293981

id	doaj-87733368391a4f2186b19b8164b911de
record_format	Article
spelling	doaj-87733368391a4f2186b19b8164b911de2020-11-25T00:10:06ZengHindawi LimitedCase Reports in Rheumatology2090-68892090-68972019-01-01201910.1155/2019/52939815293981Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case ReportYuya Fujita0Masao Nawata1Atsushi Nagayasu2Kazuki Someya3Kazuyoshi Saito4Yoshiya Tanaka5The Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe Department of Rheumatology, Tobata General Hospital, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanBaricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. After baricitinib administration, the disease activity of her rheumatoid arthritis was attenuated from the early stage of treatment, and the effect was maintained for up to 52 weeks. In addition, the skin sclerosis in systemic sclerosis showed an improvement. Regarding the influence on type 1 diabetes, the required daily dose of insulin and hemoglobin A1c (HbA1c) levels decreased. To date, no studies have demonstrated the effectiveness of baricitinib on systemic sclerosis or type 1 diabetes. We report that baricitinib was effective for systemic sclerosis and type 1 diabetes, as well as for rheumatoid arthritis, for up to 52 weeks.http://dx.doi.org/10.1155/2019/5293981
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Yuya Fujita Masao Nawata Atsushi Nagayasu Kazuki Someya Kazuyoshi Saito Yoshiya Tanaka
spellingShingle	Yuya Fujita Masao Nawata Atsushi Nagayasu Kazuki Someya Kazuyoshi Saito Yoshiya Tanaka Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report Case Reports in Rheumatology
author_facet	Yuya Fujita Masao Nawata Atsushi Nagayasu Kazuki Someya Kazuyoshi Saito Yoshiya Tanaka
author_sort	Yuya Fujita
title	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
title_short	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
title_full	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
title_fullStr	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
title_full_unstemmed	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
title_sort	fifty-two-week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease-modifying antirheumatic drug therapy that was successfully treated with baricitinib: a novel case report
publisher	Hindawi Limited
series	Case Reports in Rheumatology
issn	2090-6889 2090-6897
publishDate	2019-01-01
description	Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. After baricitinib administration, the disease activity of her rheumatoid arthritis was attenuated from the early stage of treatment, and the effect was maintained for up to 52 weeks. In addition, the skin sclerosis in systemic sclerosis showed an improvement. Regarding the influence on type 1 diabetes, the required daily dose of insulin and hemoglobin A1c (HbA1c) levels decreased. To date, no studies have demonstrated the effectiveness of baricitinib on systemic sclerosis or type 1 diabetes. We report that baricitinib was effective for systemic sclerosis and type 1 diabetes, as well as for rheumatoid arthritis, for up to 52 weeks.
url	http://dx.doi.org/10.1155/2019/5293981
work_keys_str_mv	AT yuyafujita fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT masaonawata fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT atsushinagayasu fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT kazukisomeya fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT kazuyoshisaito fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove AT yoshiyatanaka fiftytwoweekresultsofclinicalandimagingassessmentsofapatientwithrheumatoidarthritiscomplicatedbysystemicsclerosiswithinterstitialpneumoniaandtype1diabetesdespitemultiplediseasemodifyingantirheumaticdrugtherapythatwassuccessfullytreatedwithbaricitinibanove
_version_	1725409407653642240

Similar Items